儿童EB病毒原发性感染相关疾病研究进展
Related Research Progress of Epstein-Barr Virus Associated Diseases with Primary Infection in Children
DOI: 10.12677/ACM.2022.123318, PDF,  被引量   
作者: 刘茂艳, 詹 学：重庆医科大学附属儿童医院消化科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿科学重庆市重点实验室，重庆
关键词: EB病毒；慢性活动性EBV感染；EBV相关性噬血细胞性淋巴组织细胞增生症；弥漫大B细胞淋巴瘤； 伯基特淋巴瘤；EBV； Chronic Active EBV Infection； EB Virus Associated Hemophagocytic Lymphoproliferative Disorder (EBV-HLH)； Diffuse Large B-Cell Lymphoma (DLBCL)； Burkitt’s Lymphoma (BL)
摘要: EB病毒(Epstein-Barr virus, EBV)属嗜人类B淋巴细胞的DNA病毒，儿童普遍易感。一旦感染后可在人体B淋巴细胞建立潜伏性感染，终生携带病毒。在免疫力低下者体内通过多种途径导致复杂疾病，如传染性单核细胞增多症、噬血细胞性淋巴组织细胞增生症、淋巴瘤等。对儿童EB病毒原发性感染相关性疾病的研究具有重要临床意义，帮助实现患儿的早期诊治、合理治疗，避免延误病情。
Abstract: Epstein-Barr (EB) virus is a kind of DNA virus that belongs to human B lymphocytophilic DNA virus. Children are generally susceptible. Once infected, it could establish latent infection in human B lymphocytes, carrying the virus for life. In patients with impaired immunity, EBV infection could lead to complex and potentially refractory diseases, such as infectious mononucleosis, hemophagocytic lymphohistiocytosis and lymphoma. It is of great clinical significance to study the diseases related to primary Epstein-Barr virus infection in children, which can help realize early diagnosis and treatment of children and avoid delaying their illness.
文章引用：刘茂艳, 詹学. 儿童EB病毒原发性感染相关疾病研究进展[J]. 临床医学进展, 2022, 12(3): 2211-2217. https://doi.org/10.12677/ACM.2022.123318

参考文献

[1] Epstein, M.A., Achong, B.G. and Barr, Y.M. (1964) Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma. Lancet, 293, 702-703. [Google Scholar] [CrossRef] 
[2] Nowalk, A. and Green, M. (2016) Epstein-Barr Virus. Microbiology Spectrum, 4. [Google Scholar] [CrossRef] 
[3] Khan, G. and Hashim, M.J. (2014) Global Burden of Deaths from Epstein-Barr Virus Attributable Malignancies 1990-2010. Infect Agent Cancer, 9, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[4] 尹静. 儿童传染性单核细胞增多症的临床治疗方法研究进展[J]. 中国处方药, 2019,17(6): 32-34.
[5] 诸福棠实用儿科学(第8版) [J]. 中国临床医生杂志, 2015, 43(7): 47.
[6] 欧阳文献, 张慧, 刘静, 谭艳芳, 于四景, 唐莲, 等. 儿童传染性单核细胞增多症临床特征及治疗的单中心研究[J]. 中华实验和临床病毒学杂志, 2018, 32(1): 12-16.
[7] 胡岩岩, 潘家华, 周浩泉. 儿童传染性单核细胞增多症临床及实验室检查特点分析[J]. 中华全科医学, 2021, 19(9): 1510-1513.
[8] Jiang, L., Gu, Z.H., Yan, Z.X., Zhao, X., Xie, Y.Y., Zhang, Z.G., et al. (2015) Exome Sequencing Identifies Somatic Mutations of DDX3X in Natural Killer/T-Cell Lymphoma. Nature Genetics, 47, 1061-1066. [Google Scholar] [CrossRef] [PubMed]
[9] Arai, A. (2018) Chronic Active Epstein-Barr Virus Infection: A Bi-Faceted Disease with Inflammatory and Neoplastic Elements. Immunological Medicine, 41, 162-169. [Google Scholar] [CrossRef] [PubMed]
[10] Murata, T., Okuno, Y., Sato, Y., Watanabe, T. and Kimura, H. (2020) Oncogenesis of CAEBV Revealed: Intragenic Deletions in the Viral Genome and Leaky Expression of Lytic Genes. Reviews in Medical Virology, 30, Article No. e2095. [Google Scholar] [CrossRef] [PubMed]
[11] Arai, A. (2019) Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development. Frontiers in Pediatrics, 7, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[12] Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., et al. (1988) T-Cell Lymphomas Containing Epstein-Barr Viral DNA in Patients with Chronic Epstein-Barr Virus Infections. New England Journal of Medicine, 318, 733-741. [Google Scholar] [CrossRef] 
[13] Straus, S.E. (1988) The Chronic Mononucleosis Syndrome. The Journal of Infectious Diseases, 157, 405-412. [Google Scholar] [CrossRef] [PubMed]
[14] Okano, M., Kawa, K., Kimura, H., Yachie, A., Wakiguchi, H., Maeda, A., et al. (2005) Proposed Guidelines for Diagnosing Chronic Active Epstein-Barr Virus Infection. American Journal of Hematology, 80, 64-69. [Google Scholar] [CrossRef] [PubMed]
[15] Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. [Google Scholar] [CrossRef] [PubMed]
[16] 中华医学会儿科学分会感染学组, 全国儿童EB病毒感染协作组. 儿童主要非肿瘤性EB病毒感染相关疾病的诊断和治疗原则建议[J]. 中华儿科杂志, 2016, 54(8): 563-568.
[17] Arai, A. (2021) The Road to Treating Chronic Active Epstein-Barr Viral Infection. Rinsho Ketsueki, 62, 835-845.
[18] Janka, G.E. (2007) Familial and Acquired Hemophagocytic Lymphohistiocytosis. European Journal of Pediatrics, 166, 95-109. [Google Scholar] [CrossRef] [PubMed]
[19] Janka, G.E. and Lehmberg, K. (2014) Hemophagocytic Syndromes—An Update. Blood Reviews, 28, 135-142. [Google Scholar] [CrossRef] [PubMed]
[20] Bergsten, E., Horne, A., Arico, M., Astigarraga, I., Egeler, R.M., Filipovich, A.H., et al. (2017) Confirmed Efficacy of Etoposide and Dexamethasone in HLH Treatment: Long-Term Results of the Cooperative HLH-2004 Study. Blood, 130, 2728-2738. [Google Scholar] [CrossRef] [PubMed]
[21] Hayden, A., Park, S., Giustini, D., Lee, A.Y. and Chen, L.Y. (2016) Hemophagocytic Syndromes (HPSs) Including Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Systematic Scoping Review. Blood Reviews, 30, 411-420. [Google Scholar] [CrossRef] [PubMed]
[22] Nilsson, K., Klein, G., Henle, W. and Henle, G. (1971) The Establishment of Lymphoblastoid Lines from Adult and Fetal Human Lymphoid Tissue and Its Dependence on EBV. International Journal of Cancer, 8, 443-450. [Google Scholar] [CrossRef] [PubMed]
[23] 吴克复, 郑国光, 马小彤, 宋玉华. EB病毒感染的多样性及其意义[J]. 中国肿瘤临床, 2021, 48(7): 330-335.
[24] Amon, W. and Farrell, P.J. (2005) Reactivation of Epstein-Barr Virus from Latency. Reviews in Medical Virology, 15, 149-156. [Google Scholar] [CrossRef] [PubMed]
[25] Murata, T. (2014) Regulation of Epstein-Barr Virus Reactivation from Latency. Microbiology and Immunology, 58, 307-317. [Google Scholar] [CrossRef] [PubMed]
[26] Taylor, G.S., Long, H.M., Brooks, J.M., Rickinson, A.B. and Hislop, A.D. (2015) The Immunology of Epstein-Barr Virus-induced Disease. Annual Review of Immunology, 33, 787-821. [Google Scholar] [CrossRef] [PubMed]
[27] Vockerodt, M., Yap, L.F., Shannon-Lowe, C., Curley, H., Wei, W., Vrzalikova, K., et al. (2015) the Epstein-Barr Virus and the Pathogenesis of Lymphoma. The Journal of Pathology, 235, 312-322. [Google Scholar] [CrossRef] [PubMed]
[28] 王思力, 方志鸿, 黄耘, 林志娟, 苏蕊. 肿瘤坏死因子α在不同类型淋巴瘤患者中的表达及其临床预后意义[J]. 中华血液学杂志, 2014, 35(12): 1107-1110.
[29] Roemer, M.G., Advani, R.H., Ligon, A.H., Natkunam, Y., Redd, R.A., Homer, H., et al. (2016) PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 34, 2690-2697. [Google Scholar] [CrossRef] 
[30] Weiss, L.M., Strickler, J.G., Warnke, R.A., Purtilo, D.T. and Sklar, J. (1987) Epstein-Barr Viral DNA in Tissues of Hodgkin’s Disease. The American Journal of Pathology, 129, 86-91.
[31] Wu, T.C., Mann, R.B., Charache, P., Hayward, S.D., Staal, S. and Lambe, B.C., et al. (1990) Detection of EBV Gene Expression in Reed-Sternberg Cells of Hodgkin’s Disease. International Journal of Cancer, 46, 801-804. [Google Scholar] [CrossRef] [PubMed]
[32] Shanbhag, S. and Ambinder, R.F. (2018) Hodgkin Lymphoma: A Review and Update on Recent Progress. CA: A Cancer Journal for Clinicians, 68, 116-132. [Google Scholar] [CrossRef] [PubMed]
[33] Wang, H.W., Balakrishna, J.P., Pittaluga, S., Purtilo, D.T. and Sklar, J. (2019) Diagnosis of Hodgkin Lymphoma in the Modern Era. British Journal of Haematology, 184, 45-59. [Google Scholar] [CrossRef] [PubMed]
[34] (1997) A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood, 89, 3909-3918. [Google Scholar] [CrossRef] 
[35] Tracy, S.I., Habermann, T.M., Feldman, A.L., Maurer, M.J., Dogan, A., Perepu, U.S., et al. (2018) Outcomes among North American Patients with Diffuse Large B-Cell Lymphoma Are Independent of Tumor Epstein-Barr Virus Positivity or Immunosuppression. Haematologica, 103, 297-303. [Google Scholar] [CrossRef] [PubMed]
[36] Park, S., Lee, J., Ko, Y.H., Han, A., Jun, H.J., Lee, S.C., et al. (2007) The Impact of Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 110, 972-978. [Google Scholar] [CrossRef] [PubMed]
[37] Witte, H.M., Merz, H., Biersack, H., Bernard, V., Riecke, A., Gebauer, J., et al. (2020) Impact of Treatment Variability and Clinicopathological Characteristics on Survival in Patients with Epstein-Barr-Virus Positive Diffuse Large B Cell Lymphoma. British Journal of Haematology, 189, 257-268. [Google Scholar] [CrossRef] [PubMed]
[38] Oyama, T., Ichimura, K., Suzuki, R., Suzumiya, J., Ohshima, K., Yatabe, Y., et al. (2003) Senile EBV+ B-Cell Lymphoproliferative Disorders: A Clinicopathologic Study of 22 Patients. British Journal of Haematology, 27, 16-26. [Google Scholar] [CrossRef] [PubMed]
[39] Strnad, J. and Burke, J.R. (2007) IκB Kinase Inhibitors for Treating Autoimmune and Inflammatory Disorders: Potential and Challenges. Trends in Pharmacological Sciences, 28, 142-148. [Google Scholar] [CrossRef] [PubMed]
[40] Dunleavy, K., Little, R.F. and Wilson, W.H. (2016) Update on Burkitt Lymphoma. Hematology/Oncology Clinics of North America, 30, 1333-1343. [Google Scholar] [CrossRef] [PubMed]
[41] Schmitz, R., Young, R.M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., et al. (2012) Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics. Nature, 490, 116-120. [Google Scholar] [CrossRef] [PubMed]

为你推荐